ReviewViruses2022
Hepatitis B Virus Research in South Africa.
Review in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Local insights into hepatitis B Virus: genotype distribution and clinical profiles among HIV/HBV co-infected patients in Maputo, Mozambique.BMC infectious diseases · 2026Article
- Unveiling the Silent Crisis Amidst Tackling Hepatitis B in African Prisons - A Public Health Emergency.Health science reports · 2025Article
- Epidemiological and clinical profile of hepatitis B infection in ART-naïve people living with HIV in Maputo, Mozambique: a cross-sectional study.BMJ public health · 2025Article
- An Oxford Nanopore Technology-Based Hepatitis B Virus Sequencing Protocol Suitable for Genomic Surveillance Within Clinical Diagnostic Settings.International journal of molecular sciences · 2024Article
- MicroRNA levels in patients with chronic hepatitis B virus and HIV coinfection in a high-prevalence setting; KwaZulu-Natal, South Africa.BMC infectious diseases · 2024Article
- Community dialogue to enhance understanding of beliefs, behaviours and barriers to care for people living with liver disease and HBV infection in KwaZulu Natal, South Africa.Journal of virus eradication · 2024Article
- Current perspectives of viral hepatitis.World journal of gastroenterology · 2024Review
- Hepatitis B virus genotypes in precision medicine of hepatitis B-related hepatocellular carcinoma: Where we are now.World journal of gastrointestinal oncology · 2024Article
- Article
- An Oxford Nanopore Technology-Based Hepatitis B Virus Sequencing Protocol Suitable For Genomic Surveillance Within Clinical Diagnostic Settings.medRxiv : the preprint server for health sciences · 2024Article
- Prevalence of occult hepatitis B infection among treatment-naive persons living with HIV in Ghana.PloS one · 2024Article
- Co-incidence of COVID-19 and hepatocellular carcinoma during pregnancy: Double punches to disease severity and mortality?Narra J · 2023Article
- Hepatitis B virus immunity prior to and after administration of a 'booster' dose of vaccine among health-care students at a South African university.Vaccine: X · 2023Article
- Circulation of multiple hepatitis B virus genotypes in individual pregnant women seeking antenatal care in northern Ghana.Virology journal · 2023Article
- Exploring the optimal vaccination strategy against hepatitis B virus in childhood (Review).Biomedical reports · 2023Review
- Hepatitis mortality in Brazil and regions, 2001-2020: temporal trend and spatial analysis.Revista brasileira de epidemiologia = Brazilian journal of epidemiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite being vaccine-preventable, hepatitis B virus (HBV) infection remains the seventh leading cause of mortality in the world. In South Africa (SA), over 1.9 million people are chronically infected with HBV, and 70% of all Black chronic carriers are infected with HBV subgenotype A1. The virus remains a significant burden on public health in SA despite the introduction of an infant immunization program implemented in 1995 and the availability of effective treatment for chronic HBV infection. In addition, the high prevalence of HIV infection amplifies HBV replication, predisposes patients to chronicity, and complicates management of the infection. HBV research has made significant progress leading to better understanding of HBV epidemiology and management challenges in the SA context. This has led to recent revision of the national HBV infection management guidelines. Research on developing new vaccines and therapies is underway and progress has been made with designing potentially curative gene therapies against HBV. This review summarizes research carried out in SA on HBV molecular biology, epidemiology, treatment, and vaccination strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.